AstraZeneca: AstraZeneca sets the stage for a brighter future

BUY, Fair Value 3400p vs. 3440p (+11%)

News published on February Friday 1, 2013
Share on

Although we are making some downward adjustments to our 2013 figures from revenues down to the Core EPS (slightly lower sales, opex increase, no share buy-back), our FV is marginally impacted as the longer term is unaffected and financial leverage higher. Moreover our thesis for a return to growth is now in place and should gain ground no later than March 21st. 3,000p is a good entry point.


Full report available to subscribers
Please contact marketing@bryangarnier.fr

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities